My watch list  

611 Current news from israel

matching the following criteria

Evolva completes Allylix acquisition


Evolva Holding SA announces the completion of the acquisition of Allylix, Inc., after which Allylix will be a wholly-owned subsidiary of Evolva. This acquisition was announced on 18 November 2014. Evolva will acquire Allylix in return for an overall consideration of 46 million newly-issued Evolva ...


image description
Why tumours exhibit fatty degeneration


In cases of clear cell renal cell carcinoma – the most common type of renal cell carcinoma – the cancer cells become fatty. The reasons for this were long unclear, but ETH researchers have now found the cause: important cell structures in lipometabolism degrade more rapidly. In kidney cancer and ...


Orphan Drug Status Granted to Vesimune for Bladder Cancer


Telormedix announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Vesimune for the treatment of carcinoma in situ (CIS) in the bladder.The FDA grants orphan drug status to products for rare diseases and defines a rare disease as one with a prevalence of ...


image description
DNA survives critical entry into Earth's atmosphere


Applied to the outer shell of the payload section of a rocket using pipettes, small, double-stranded DNA molecules flew into space from Earth and back again. After the launch, space flight, re-entry into Earth's atmosphere and landing, the so-called plasmid DNA molecules were still found on all ...


Immunotherapy set to revolutionise cancer treatment


Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland.“We expect that the new possibilities of immunotherapy will substantially ...


Evolva to acquire Allylix


Evolva Holding SA has agreed to acquire San Diego-based Allylix, Inc., a privately held yeast fermentation company with a focus on high-value ingredients, in an all-stock transaction. The acquisition will immediately expand Evolva’s product and IP portfolio and enhance the competitiveness of ...


MaxiVAX starts anti-cancer clinical trial based on active immunotherapy

Novel high-tech anti-cancer vaccination therapy boosts the patient’s own immune response


MaxiVAX SA is conducting a clinical phase 1 trial at the Geneva University Hospitals with its proprietary cancer vaccination MVX-ONCO-1 in 15 patients suffering from various cancers at an advanced stage.The Immuno-Oncology therapeutic protocol and product of MaxiVAX is based on boosting the ...


Oncoethix starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors and Glioma


Oncoethix announced that the first patient has been enrolled in an international, open-label, non-randomized, multicenter Phase 1b trial of OTX015 in advanced solid tumors. The trial will be coordinated by Dr Lillian Siu, MD, of the Princess Margaret Hospital, Toronto, Canada, who is Professor ...


New antibiotic in mushroom that grows on horse dung


Microbiologists and molecular biologists at ETH Zurich and the University of Bonn have discovered a new agent in fungi that kills bacteria. The substance, known as copsin, has the same effect as traditional antibiotics, but belongs to a different class of biochemical substances. Copsin is a ...


Merck: Executive Board Member Oschmann Elected President of IFPMA

Presidency at IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) under overarching theme of “Accelerating Access”


Stefan Oschmann, CEO Pharma and Member of the Executive Board of Merck, was elected President of IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) during 27th IFPMA Assembly in New York, U.S.A. The term of office of Oschmann, who has been Vice President at IFPMA ...


Page 1 From 62
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE